By Hongjiang Li | Jan 25, 2019 | 10:16 PM GMT Pfizer Inc. (NYSE:PFE) launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China.
US pharma company Shanghai MediTrust Health has launched US 's first pay-for-performance insurance product, with breast cancer drug Ibrance palbociclib, in partnership with PICC Health Insurance and PICC Health Insurance . The programme is being rolled out in 500 cities, and is available to a maximum of 34 patients with no previous first -line endocrine therapy treatment. Pfizer said those experiencing disease progression or metastasis within the first 126 days of beginning Ibrance treatment, or in combination with an aromatase inhibitor, will be reimbursed with up to 33.5% of the cost.